| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 318.38 | 52.9% |
| Total Income | 331.62 | 50.5% |
| Expenditure | 199.13 | 38.9% |
| PBT | 132.49 | 72.2% |
| Net Profit | 98.98 | 69.6% |
| OPM | 35.96% | 7.05pp |
| NPM | 29.85% | 3.37pp |
| EPS | 5.71 | 69.9% |
Blue Jet Healthcare Announces Q3 & 9M FY25 Results: Highest Ever PAT recorded at Rs. 990 mn, Revenue at Rs. 3,184 mn; a jump of 90.9% YoY
29 Jan 2025 · 29 Jan 2025, 10:48 pm
Summary
Blue Jet Healthcare Limited (BLUEJET) reported financial results for the quarter and nine months ended December 31, 2024. The company recorded the highest ever PAT at Rs. 990 mn for the quarter, a growth of 208% on a YoY basis. The revenue for the quarter stood at Rs. 3,184 mn, showing a 90.9% YoY growth. The EBITDA margin came at 39%, up by 630bps YoY. The success was driven by the Pharmaceutical Intermediate business and the High Intensity Sweetener business. The company commissioned one manufacturing block at Ambernath in the quarter.
Key Highlights
- 1
Revenue from operations for Q3 FY25 stood at Rs. 3,184 mn, showing a 90.9% YoY growth
- 2
EBITDA for the quarter came at Rs. 1,240 mn, up 127.2% YoY
- 3
Company posted highest ever PAT for the quarter at Rs. 990 mn
- 4
Commissioned one manufacturing block at Ambernath in the quarter
- 5
Robust Liquidity with Cash & Cash equivalent and Treasury Investments stands at Rs 3,313 Mn as on 31 December 2024
Management Comments
Mr. Shiven Arora
Blue Jet witnessed a remarkable quarter delivering strong performance as we clocked a revenue of Rs. 3,184 mn, giving a 91% YoY growth as compared to the same quarter last year. PAT for the quarter came at Rs. 990 mn with a growth of 208% on a YoY basis. The EBITDA margin came at 39%, showcasing our efforts to strengthen our financial foundation and operational efficiencies. This success was largely driven by the Pharmaceutical Intermediate business and the High Intensity Sweetener business. We commissioned one manufacturing block at Ambernath in the quarter, a significant milestone for us which will help us reap benefits in the coming quarters. Even Amidst ongoing industry challenges, we are poised for quality growth in FY25.
Informational and educational content only. Not investment advice.